Ocular Therapeutix, Inc.
OCUL
$7.45
-$0.49-6.17%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.03% | 6.45% | 11.90% | 15.79% | 13.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.03% | 6.45% | 11.90% | 15.79% | 13.50% |
| Cost of Revenue | 100.89% | 71.57% | 40.03% | 21.61% | 14.37% |
| Gross Profit | -780.91% | -743.44% | -256.14% | -59.76% | -21.28% |
| SG&A Expenses | 37.26% | 23.62% | 15.92% | 4.46% | 3.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.23% | 45.40% | 26.65% | 12.03% | 8.20% |
| Operating Income | -108.51% | -72.91% | -36.24% | -9.69% | -4.74% |
| Income Before Tax | -139.68% | -159.98% | -52.50% | -29.78% | -13.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -139.68% | -159.98% | -52.50% | -29.78% | -13.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -139.68% | -159.98% | -52.50% | -29.78% | -13.65% |
| EBIT | -108.51% | -72.91% | -36.24% | -9.69% | -4.74% |
| EBITDA | -111.58% | -73.61% | -35.24% | -8.23% | -3.73% |
| EPS Basic | -25.00% | -52.56% | 5.54% | 3.78% | -9.25% |
| Normalized Basic EPS | 11.62% | -6.16% | 8.35% | 6.64% | -28.61% |
| EPS Diluted | -0.56% | -15.20% | -12.15% | -13.92% | -23.05% |
| Normalized Diluted EPS | 10.68% | -8.93% | 8.31% | 5.15% | -33.41% |
| Average Basic Shares Outstanding | 98.24% | 76.15% | 49.20% | 21.33% | 3.82% |
| Average Diluted Shares Outstanding | 94.72% | 69.87% | 48.30% | 18.76% | 0.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
